The approval makes dupilumab the first biologic available in the United States to treat uncontrolled moderate-to-severe atopic dermatitis in this age group.
Dupilumab, an anti-IL-4 and anti-IL-13 monoclonal antibody, is indicated in Europe for the treatment of moderate to severe atopic dermatitis that requires systemic treatment.
Ophthalmologists do not need to routinely delay ophthalmologic procedures in their patients whose blood pressure is not well-controlled, according to study of Scandinavian patient registry data.